Literature DB >> 8618233

Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.

C Leonetti1, I D'Agnano, F Lozupone, A Valentini, T Geiser, G Zon, B Calabretta, C Citro G, G Zupi.   

Abstract

BACKGROUND: Phosphorothioate oligodeoxynucleotides ([S]ODNs) contain a modified internucleoside phosphate backbone. Antisense [S]ODNs targeted to specific oncogenes have been used with some therapeutic success in animal models human leukemia; however, the potential for antisense [S]ODN treatment of solid tumors has only recently been explored.
PURPOSE: We evaluated the effects of antisense [S]ODNs targeted to the c-myc oncogene on the proliferation of human melanoma cells in vitro and on the growth of human melanoma xenografts in CD-1 nude (nu/nu) mice,
METHODS: The effects of 15-mer [S]ODNs containing c-myc sense, c-myc antisense, and two different scrambled sequences on the proliferation and viability of cultures of three established human melanoma cell lines (M14, JR8, and PLF2) were determined by measuring cell numbers and use of the trypan blue exclusion test. The induction of apoptosis in these cells following treatment with [S]ODNs was evaluated by fluorescence-activated cell sorter (FACS) analysis. FACS analysis was also used to determine the effects of [S]ODN treatment on the proliferation of primary cultures of a human melanoma explant (NG cells). The expression of c-Myc protein in cultured NG cells after treatment with [S]ODNs was examined by western blot analysis. The antitumor activity and the toxic effects of several [S]ODN treatment regimens were monitored by measuring differences in tumor weight (percent tumor weight inhibition), tumor growth rate (tumor growth inhibition), animal lifespan (percent increase in lifespan), the number of toxic deaths and the median number of long metastases in treated and control mice bearing NG xenografts. c-Myc protein expression in NG tumor cells following [S]ODN treatment was evaluated by FACS analysis, and the extent of apoptosis in these cells was determined by FACS analysis and morphologic examination.
RESULTS: Treatment with antisense [S]ODNs, but not the others, inhibited the growth of all tested melanoma cultures in vitro; FACS analysis revealed that growth inhibition was associated with the induction of apoptosis. Antisense [S]ODN treatment also led to reduced celluLar levels of c-Myc protein. In vivo, [S]ODN antitumor activity and toxicity were dose and schedule dependent; however, only antisense [S]ODNs exhibited antitumor activity. Mice bearing NG xenografts treated with antisense [S]ODNs showed a marked inhibition of tumor growth, a reduction in the number of long metastases, and an increase in life span. Reduced levels of c-Myc protein and increased levels of apoptosis were also observed in NG tumor cells following antisense [S]ODN treatment.
CONCLUSIONS: treatment of human melanoma cells and solid tumors with antisense [S]ODNs targeted to c-Myc inhibits their growth and is associated with the induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8618233     DOI: 10.1093/jnci/88.7.419

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  23 in total

Review 1.  Preclinical and clinical pharmacology of antisense oligonucleotides.

Authors:  E G Marcusson; B R Yacyshyn; W R Shanahan; N M Dean
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

2.  Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src.

Authors:  N Aziz; H Cherwinski; M McMahon
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  Intravenous IGF-I receptor antisense reduces IGF-IR expression and diminishes pressor responses to angiotensin II in conscious normotensive rats.

Authors:  Tien Thuy Nguyen; Paul James White
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 4.  Synthetic oligonucleotides: useful molecules? A review.

Authors:  A Calogero; G A Hospers; N H Mulder
Journal:  Pharm World Sci       Date:  1997-12

5.  TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells.

Authors:  Annamaria Biroccio; Julien Cherfils-Vicini; Adeline Augereau; Sébastien Pinte; Serge Bauwens; Jing Ye; Thomas Simonet; Béatrice Horard; Karine Jamet; Ludovic Cervera; Aaron Mendez-Bermudez; Delphine Poncet; Renée Grataroli; Claire T'kint de Rodenbeeke; Erica Salvati; Angela Rizzo; Pasquale Zizza; Michelle Ricoul; Céline Cognet; Thomas Kuilman; Helene Duret; Florian Lépinasse; Jacqueline Marvel; Els Verhoeyen; François-Loïc Cosset; Daniel Peeper; Mark J Smyth; Arturo Londoño-Vallejo; Laure Sabatier; Vincent Picco; Gilles Pages; Jean-Yves Scoazec; Antonella Stoppacciaro; Carlo Leonetti; Eric Vivier; Eric Gilson
Journal:  Nat Cell Biol       Date:  2013-06-23       Impact factor: 28.824

6.  The therapeutic effects of recombinant adenovirus RA538 on human gastric carcinoma cells in vitro and in vivo.

Authors:  Jie-Ping Chen; Chen Lin; Cai-Pu Xu; Xue-Yan Zhang; Ming Wu
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

7.  Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression.

Authors:  Delisha A Stewart; Xiaohua Xu; Shelia D Thomas; Donald M Miller; Xiaohou Xu
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

8.  Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A.

Authors:  G Tortora; R Caputo; V Damiano; R Bianco; S Pepe; A R Bianco; Z Jiang; S Agrawal; F Ciardiello
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

9.  EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.

Authors:  Gianluca Sala; Ilario Giovanni Rapposelli; Reza Ghasemi; Enza Piccolo; Sara Traini; Emily Capone; Cosmo Rossi; Angela Pelliccia; Annalisa Di Risio; Maurizia D'Egidio; Nicola Tinari; Raffaella Muraro; Stefano Iacobelli
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

10.  DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene.

Authors:  Giuseppina M Carbone; Eileen McGuffie; Sara Napoli; Courtney E Flanagan; Chiara Dembech; Umberto Negri; Federico Arcamone; Massimo L Capobianco; Carlo V Catapano
Journal:  Nucleic Acids Res       Date:  2004-04-30       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.